Quality of Life and psychopathology in adults who underwent Hematopoietic Stem Cell Transplantation (HSCT) in childhood: a qualitative and quantitative analysis.

Background: Patients who undergo pediatric Hematopoietic Stem Cell Transplantation (HSCT) may experience long-term psychological sequelae and poor Quality of Life (QoL) in adulthood. This study aimed to investigate subjective illness experience, QoL, and psychopathology in young adults who have survived pediatric HSCT. Method: The study involved patients treated with HSCT in the Hematology-Oncology Department between 1984 and 2007. Psychopathology and QoL were investigated using the SCL-90-R and SF-36. Socio-demographic and medical information was also collected. Finally, participants were asked to write a brief composition about their experiences of illness and care. Qualitative analysis of the texts was performed using T-LAB, an instrument for text analysis that allows the user to highlight the occurrences and co-occurrences of lemma. Quantitative analyses were performed using non-parametric tests (Spearman correlations, Kruskal-Wallis and Mann-Whitney tests). Results: Twenty-one patients (9 males) participated in the study. No significant distress was found on the SCL-90 Global Severity Index, but it was found on specific scales. On the SF-36, lower scores were reported on scales referring to bodily pain, general health, and physical and social functioning. All the measures were significantly (p < 0.05) associated with specific socio-demographic and medical variables (gender, type of pathology, type of HSCT, time elapsed between communication of the need to transplant and effective transplantation, and days of hospitalization). With regard to the narrative analyses, males focused on expressions related to the body and medical therapies, while females focused on people they met during treatment, family members, and donors. Low general health and treatment with autologous HSCT were associated with memories about chemotherapy, radiotherapy, and the body parts involved, while high general health was associated with expressions focused on gratitude (V-Test \ub1 1.96). Conclusion: Pediatric HSCT survivors are more likely to experience psychological distress and low QoL in adulthood compared with the general population. These aspects, along with survivors' subjective illness experience, show differences according to specific medical and socio-demographic variables. Studies are needed in order to improve the care and long-term follow-up of these families

Identificação do gene phlD e análise da diversidade genética em isolados de Pseudomonas spp. pertencentes ao grupo fluorescente.

RESUMO – Bactérias do gênero Pseudomonas spp. pertencentes ao grupo fluorescente têm sido mencionadas como eficazes no controle de patógenos que atacam o sistema radicular de plantas. Desse modo, este trabalho se propôs a identificar isolados de Pseudomonas spp. fluorescentes sintetizadores de 2,4-diacetilfloroglucinol (2,4- DAPG), um antibiótico que apresenta atividade contra diversos patógenos radiculares de plantas, além de avaliar a diversidade genética desse gênero de bactérias utilizando a técnica de PCR-RFLP 16S RNAr. Pela técnica de PCR foi amplificado um fragmento do gene phlD, envolvido na síntese do 2,4-DAPG. Para o PCR-RFLP, o gene ribossomal 16S foi amplificado e o produto do PCR foi digerido com a enzima de restrição AluI. De um total de 1.274 isolados analisados, seis apresentaram o gene phlD, revelando que a incidência de Pseudomonas spp. produtoras de 2,4-DAPG é baixa nos solos do Paraná. A análise da diversidade genética, realizada em 50 isolados pela comparação dos padrões de restrição do gene 16S RNAr, revelou que bactérias isoladas de diferentes culturas vegetais apresentam elevada diversidade genética, sendo identificados 11 genótipos distintos

Seleção de bactérias promotoras para produção orgânica de soja e trigo.

Errata/Autoria: BETTI, L. A

Identificação e eficiência de Bacillus spp. inibidor do crescimento de Macrophomina phaseolina.

O presente trabalho visou quantificar a eficiência do gênero Bacillus no controle de Macrophomina phaseolina

Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program

Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir ± Ribavirin for 12 weeks in 213 HIV-HCV genotype 1 patients. Data on efficacy and tolerability of this strategy in HIV patients have been reported until now only in 43 non cirrhotic HIV subjects

Ocupação nodular com estirpes de Bradyrhizobium spp. em cultivares de soja sob diferentes disponibilidades hídricas a campo.

A ocupação nodular com estirpes de Bradyrhizobium spp. em cultivares de soja sob diferentes disponibilidades hídricas foi analisada na safra 2007/08 em Londrina-PR. O delineamento experimental utilizado foi o de blocos ao acaso com parcelas sub-divididas, com quatro repetições. As parcelas principais receberam três tratamentos (1- déficit hídrico nos estádios reprodutivos - DHER, 2- condições normais de campo - CNC e 3- condições ótimas de umidade - IRR); e as sub-parcelas, dez cultivares de soja. Os nódulos foram tipificados pelo método de ELISA, com anti-soros das estirpes SEMIA 5079, SEMIA 5080, SEMIA 587 e SEMIA 5019. Não houve diferença significativa para a ocupação nodular em relação à disponibilidade hídrica, porém, estes resultados podem estar relacionados ao fato da indução de déficit hídrico ter ocorrido na fase reprodutiva, quando a nodulação já estava estabelecida. As estirpes inoculadas, quando consideradas em conjunto, foram mais competitivas na nodulação do que as estirpes naturalizadas no solo, sendo a SEMIA 587 a que apresentou maior ocupação nodular. Não foi possível identificar uma estirpe mais tolerante ao déficit hídrico

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virological failure using Kaplan–Meier curves. We used Cox regression model to investigate predictors of DTG discontinuation. Results: About 1679 individuals (932 ART-naïve, 747 TE) were included. The one- and two-year probabilities (95% CI) of DTG discontinuation were 6.7% (4.9 to 8.4) and 11.5% (8.7 to 14.3) for ART-naïve and 6.6% (4.6 to 8.6) and 7.6% (5.4 to 9.8) for TE subjects. In both ART-naïve and TE patients, discontinuations of DTG were mainly driven by toxicity with an estimated risk (95% CI) of 4.0% (2.6 to 5.4) and 2.5% (1.3 to 3.6) by one year and 5.6% (3.8 to 7.5) and 4.0% (2.4 to 5.6) by two years respectively. Neuropsychiatric events were the main reason for stopping DTG in both ART-naïve (2.1%) and TE (1.7%) patients. In ART-naïve, a concomitant AIDS diagnosis predicted the risk of discontinuing DTG for any reason (adjusted relative hazard (aRH)&nbsp;=&nbsp;3.38, p&nbsp;=&nbsp;0.001), whereas starting DTG in combination with abacavir (ABC) was associated with a higher risk of discontinuing because of toxicity (aRH&nbsp;=&nbsp;3.30, p&nbsp;=&nbsp;0.009). TE patients starting a DTG-based dual therapy compared to a triple therapy had a lower risk of discontinuation for any reason (adjusted hazard ratio (aHR)&nbsp;=&nbsp;2.50, p&nbsp;=&nbsp;0.037 for ABC-based triple-therapies, aHR&nbsp;=&nbsp;3.56, p&nbsp;=&nbsp;0.012 for tenofovir-based) and for toxicity (aHR&nbsp;=&nbsp;5.26, p&nbsp;=&nbsp;0.030 for ABC-based, aHR&nbsp;=&nbsp;6.60, p&nbsp;=&nbsp;0.024 for tenofovir-based). The one- and two-year probabilities (95% CI) of virological failure were 1.2% (0.3 to 2.0) and 4.6% (2.7 to 6.5) in the ART naïve group and 2.2% (1.0 to 3.3) and 2.9% (1.5 to 4.3) in the TE group. Conclusions: In this large cohort, DTG showed excellent efficacy and optimal tolerability both as first-line and switching ART. The low risk of treatment-limiting toxicities in ART-naïve as well as in treated individuals reassures on the use of DTG in everyday clinical practice